Wednesday, April 28, 2021 Daily Archives

eBook: mRNA — Revisiting a Technology That Has Rocketed into Success

by , , , , and

At the end of 2018, BPI published its first eBook about mRNA drug products — and quite a lot has happened since then! Our initial report highlighted companies working on mRNA therapeutics for cystic fibrosis, heart disease, and cancer, as well as vaccines. The latter approach took off in 2020 with the advent of SARS-CoV-2 and the COVID-19 pandemic, and in a stunningly short time, the biopharmaceutical industry has learned much about manufacture, formulation, product design, and distribution of mRNA…

April 28, 2021

Sanofi to fill-finish up to 200m doses of Moderna’s COVID vaccine

by

Sanofi will supply fill-finish services for up to 200 million doses of Moderna’s COVID-19 vaccine mRNA-1273. French pharma giant Sanofi will use its site in Ridgefield, New Jersey to support manufacturing of Moderna’s cell-free COVID-19 vaccine, 1273, approved under Food and Drug Administration (FDA) emergency authorization. According to the firm, it could help manufacture up to 200 million doses of the COVID-19 vaccine starting from September 2021 through to April 2022. “While our utmost priority remains to advance our two COVID-19 vaccine…

April 28, 2021

Vendors continuing to reap the COVID windfall

by

Danaher expects COVID-19 vaccine and therapy-related revenue for its bioprocess businesses Pall and Cytiva to reach $2 billion, while the pandemic fuelled “an exceptionally strong start†to Sartorius’s 2021. In June last year, the evolving coronavirus pandemic was marked out as a $14 billion opportunity for bioprocess vendors by analysts. Ten months on, with several vaccines and therapies being used commercially and several more moving through the clinic, the service firms are experiencing unprecedented demand for their equipment and tools…

April 28, 2021